Lorazepam clinical trials
Lorazepam is named as an intervention in 5 current clinical trials in our Canada, Denmark and Brazil registers. 1 is recruiting patients now. The most common phase is Phase 2/3. The sponsor with the most trials is Lone Baandrup (1). The most-studied condition is Agitation.
Where Lorazepam is approved
All regulators →Of the three regulators tracked here, the first to approve Lorazepam was the US, on 30 Sep 1977. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Lorazepam patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Lorazepam, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 1 listed patent; the last listed expires 8 Jan 2034 (US 8999393).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Lorazepam
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Lorazepam works
All drug targets →- GABA-A receptor; anion channel positive allosteric modulator Positive allosteric modulatorTarget: GABA-A receptor; anion channelChEMBL only
- AgitationPhase 3
- PainPhase 3
- SeizurePhase 3
- VertigoPhase 3
- Bipolar disorderPhase 3
- ConvulsionPhase 3
- Generalized anxiety disorderPhase 3
- Panic disorderPhase 3
- SchizophreniaPhase 3
- SedationPhase 2/3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL580, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 5884, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Lorazepam
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 5 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Lorazepam
- ATC code
- N05BA06
- ChEMBL
- CHEMBL580
- DrugBank
- DB00186
- PubChem CID
- 3958
- CAS number
- 846-49-1
- FDA UNII
- O26FZP769L
- Wikidata
- Q408265
- Wikipedia
- Lorazepam
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Lorazepam
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Lorazepam across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
5 single-substance products containing Lorazepam on the HPRA medicines list.
- Ativan 1 mg TabletsPfizer Healthcare Ireland Unlimited Company · PA0822/090/001 · Marketed
- Lorazepam Macure 4 mg/ml solution for injectionMacure Pharma ApS · PA23199/002/001 · Marketed
- Lorazepam 1mg tabletsAspire Pharma (Malta) Limited · PA23142/007/001 · Not marketed
- Lorazepam 2.5 mg tabletsAspire Pharma (Malta) Limited · PA23142/007/002 · Not marketed
- Xilmac 4 mg/ml Solution for injectionMacure Healthcare Limited · PA23314/001/001 · Not marketed
Supply shortages
- Lorazepam InjectionUS (FDA) · Current · updated 3 Nov 2026
Conditions studied with Lorazepam
8 conditionsSponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 3 | 0 |
| Clinical trials in Denmark | 1 | 1 |
| Clinical trials in Brazil | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Lorazepam trials
How many clinical trials are testing Lorazepam?
5 current trials in our Canada, Denmark and Brazil registers name Lorazepam as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Lorazepam trials recruiting patients?
Yes. 1 of the 5 trials is recruiting: 1 with sites in Denmark. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Lorazepam clinical trials?
Lone Baandrup (1), University Health Network, Toronto (1), London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) and University of Manitoba (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Lorazepam licensed in Ireland?
Yes. The HPRA medicines list includes 5 single-substance products containing Lorazepam, for example Ativan 1 mg Tablets (Pfizer Healthcare Ireland Unlimited Company). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Lorazepam shortage?
The registers we track list 1 entry for Lorazepam: US FDA: current. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lorazepam works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lorazepam works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lorazepam (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.